As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for samples received on April 20, at the Charlotte, Dallas, Phoenix, St. Louis and Tampa laboratories. Babesia is a selective pooled NAT test, required for all blood donations collected by May 2020, in 14 States and the District of Columbia. To help you understand the requirements, CTS will host a Babesia Implementation and Review webinar on March 3, 2020 at 11:00 am CST. If you are interested in attending, please contact your Customer Service Manager for invitation details.
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...